Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last kr154.50 DKK
Change Today +1.50 / 0.98%
Volume 52.7K
As of 7:14 AM 10/6/15 All times are local (Market data is delayed by at least 15 minutes).

zealand pharma a/s (ZEAL) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/30/15 - kr166.00
52 Week Low
10/16/14 - kr58.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ZEALAND PHARMA A/S (ZEAL)

Related News

No related news articles were found.

zealand pharma a/s (ZEAL) Related Businessweek News

No Related Businessweek News Found

zealand pharma a/s (ZEAL) Details

Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide medicines in Denmark. It offers Lyxumia (Lixisenatide), a once-daily prandial GLP-1 receptor agonist for the treatment of type 2 diabetes. The company is also developing Lantus (LixiLan), which is in Phase III clinical trials for the treatment of type 2 diabetes; Danegaptide that is in Phase II clinical trials to treat cardiac reperfusion injuries; and Elsiglutide, a GLP-2 receptor agonist, which is in Phase IIb clinical trials for the treatment of chemotherapy-induced diarrhea in patients with colorectal cancer. In addition, it is developing ZP4207 that is in Phase I clinical trials to treat hypoglycemia in diabetes; and ZP2929, a dual acting glucagon/GLP-1 peptide receptor agonist, which is in Phase I clinical trials for the treatment of diabetes and/or obesity. The company has license agreements and partnerships with Sanofi S.A., Helsinn Healthcare S.A., Boehringer Ingelheim International GmbH, and Eli Lilly. Zealand Pharma A/S was founded in 1997 and is based in Copenhagen, Denmark.

109 Employees
Last Reported Date: 08/28/15
Founded in 1997

zealand pharma a/s (ZEAL) Top Compensated Officers

Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: kr2.1M
Compensation as of Fiscal Year 2014.

zealand pharma a/s (ZEAL) Key Developments

Zealand Pharma A/S Receives Approval from U.S. Food and Drug Administration for New Drug Application for Lixisenatide (Lyxumia(R))

Zealand Pharma A/S announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for lixisenatide in the U.S. As stated earlier, Sanofi submitted the NDA at the end of July 2015, and the FDA's acceptance of the application is an important milestone in the U.S. regulatory review process for lixisenatide. Lixisenatide is an investigational once-daily prandial GLP-1 receptor agonist invented by Zealand for the treatment of patients with Type 2 diabetes. Lixisenatide is currently available for adult patients in over 40 countries outside the U.S., marketed as Lyxumia(r) by Sanofi under a global license agreement with Zealand. Sanofi has announced that the proprietary name for lixisenatide is under consideration in the U.S.

Zealand Pharma A/S Initiates Clinical Phase II Development Program for Proprietary Peptide Therapeutic, ZP1848, for Treatment of Short Bowel Syndrome

Zealand Pharma A/S announced the initiation of a clinical Phase II development program for its proprietary peptide therapeutic, ZP1848, for the treatment of Short Bowel Syndrome (SBS). ZP1848 is a long-acting, stable and soluble GLP-2 receptor agonist invented and wholly owned by the company. In preclinical studies, ZP1848 has shown efficacy on small intestine growth and demonstrated the physico-chemical properties of a long-acting, stable and soluble peptide therapeutic with the potential for convenient administration in liquid formulation. The company has also investigated ZP1848 in a combined single (SAD) and multiple (MAD) ascending dose Phase I trial. Results from this trial demonstrated that ZP1848 is safe and well tolerated with a supportive effect on bowel function. The attractive potential identified for ZP1848 in Short Bowel Syndrome and the opportunity for the company to initiate a clinical Phase II development program in this specialist care indication is an important step in line with the company's strategic focus on increasing the value of its proprietary pipeline. The Phase II Proof-of-Concept trial is planned as a randomized, double-blind, dose-finding trial to investigate the clinical efficacy and safety of ZP1848 in patients with SBS. The primary objective of the trial will be to assess intestinal absorption. The first patients are planned to be enrolled and dosed in the first quarter of 2016.

Zealand Pharma A/S Announces Results from Clinical Phase Ib Trial with its Novel Glucagon Analogue

Zealand Pharma A/S announced that results from a clinical Phase Ib trial with its novel glucagon analogue, ZP4207 show good safety and tolerability after multiple dosing. In addition, it was shown that ZP4207 leads to clinically relevant increases in blood glucose levels. ZP4207, which was invented and is wholly-owned by Zealand, has shown a good stability profile in liquid formulation, supporting its potential as a product immediately ready for use. The randomized, double-blind and placebo-controlled Phase Ib trial was conducted by Zealand at a clinical diabetes center in Germany and enrolled 24 healthy volunteers. The trial objectives were primarily to evaluate safety and tolerability and secondarily to assess pharmacokinetics and pharmacodynamics of ZP4207 after multiple dosing. Participants in the trial received three different doses of ZP4207, each over 5 consecutive days. The trial was funded under a USD 1.8 million grant from the Helmsley Charitable Trust to support preclinical and initial clinical activities related to the multiple-dose version of ZP4207.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZEAL:DC kr154.50 DKK +1.50

ZEAL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ZEAL.
View Industry Companies

Industry Analysis


Industry Average

Valuation ZEAL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 44.5x
Price/Book 21.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 37.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZEALAND PHARMA A/S, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at